Sentences with phrase «further share price increases»

In order to protect the majority of your profit, whilst benefiting from further share price increases, you could place a trailing stop order to sell 1,000 shares 2 % below market.

In a bear market, an oversold position is generally indicated around an RSI of 10, with resistance to further share price increases coming in at around an RSI level of 50 to 60.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Now, investors are eyeing an OPEC meeting on November 27 to see whether the organization could even cut prices further in an attempt to retain its global market share, particularly in the face of competition from the U.S. where oil production has increased thanks to the shale gas industry.

UPDATE: The Washington Post covers the story on Wednesday, May 14, noting that Hachette may be forced to «relent on the price at which it sells books to Amazon, squeezing its slim profit margins even further» and that, as Amazon's market share increases, «if there's no real choice of where to buy things, maybe there should be some other way to retain pricing power for those who produce goods in the first place.»

Conditions for gold shares improved, based on increased evidence for economic softness and a further pullback in gold stock prices.

Positive news, increases in price targets, and investors rallying behind new prospects from further monetization of its users through advertising have all helped the shares rise.

Although the company has indicated it will undertake a $ 5M stock buyback, which will likely push the stock price up further, the stock has reached our estimate of its liquidation value, so the buyback will not increase the per share liquidation value at this level.

Quite obviously, growing the asset management business & increasing the share price / NAV has become a far more lucrative proposition now than attempting to gouge shareholders.

We also want to make clear that any attempt by you to merge or otherwise combine with any other public or private company, thereby inflating the enterprise value of the combined entity without increasing the share price for your existing stockholders, would further erode any potential value in Northstar shares that could be realized through a cash dividend or share buyback.

I think it's reasonable to expect a far larger increase in the share price!

The dividend will likely increase further and given FCF and its position, a yield of over 4 % is possible based on the current share price at Cisco.

Actually, this probably understates Upside Potential, which would be enhanced by i) any further share buybacks (at a discount to NAV), ii) any NAV increases, based on income / capital gains (I won't speculate on this, but note the v positive income tailwind highlighted previously), and iii) a value realization «event «would likely offer a share price premium, or even NAV.